Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by NewAmsterdam Pharma N.V NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 09, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer April 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress March 25, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD March 12, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 26, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors January 08, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces 2024 Strategic Priorities January 04, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights November 13, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer October 23, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation September 21, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference September 20, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire Tickers NAMS NAMSW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.